Biogen Inc. is a Biotechnology & Neuroscience company headquartered in Cambridge, Massachusetts, United States. In FY2025, it reported $9.9B in site-standard revenue and about $1.29B in net income. It had about 7,500 employees and is led by Christopher A. Viehbacher.
How Biogen Makes Money
Biogen makes money from product sales, collaboration revenue, royalties, and profit-sharing arrangements tied to neuroscience, rare disease, immunology, and Alzheimer's programs. Its customers include patients, neurologists, hospitals, specialty pharmacies, payers, health systems, and biopharma partners. The key driver is a portfolio of neurology products and partner programs, with Tysabri, Spinraza, anti-CD20 royalties, and newer launches shaping the revenue mix.
Biogen Strategy
Biogen competes by concentrating on specialist neuroscience markets, lifecycle management, targeted business development, payer access, and scientific credibility in hard-to-treat diseases. The strategic focus is stabilizing mature revenue, scaling newer launches, advancing Alzheimer's and rare-neurology assets, and funding R&D with disciplined costs.
Biogen Financials
Biogen's FY2025 10-K reports $9.8906B in revenue, $1.2929B in net income, and about 7,500 employees worldwide. Biogen reported FY2025 net income of $1.2929B.
Biogen Competitive Position
Biogen's advantage is deep neurology expertise, long-standing specialist relationships, experience with complex biologics, and an established commercial infrastructure in rare and neurodegenerative diseases. It competes with Roche, Novartis, Gilead Sciences and other companies across Biotechnology & Neuroscience.
Biogen Risks
Biogen's biggest risk is erosion in mature multiple-sclerosis franchises, uncertain uptake for newer neurodegeneration products, reimbursement friction, and pipeline execution risk.
